Llombart-Cussac, Antonio <br/><br/>
A prognostic factor index for overall survival in patients receiving first-line chemotherapy for HER2-negative advanced breast cancer: an analysis of the ATHENA trial.  [electronic resource] 

 -  Breast (Edinburgh, Scotland)  Oct 2014 
 - 656-62 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1532-3080 
<br/><br/><label>Standard No.: </label>10.1016/j.breast.2014.06.017  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Antibodies, Monoclonal, Humanized--administration & dosage<br/>Antineoplastic Agents--administration & dosage<br/>Antineoplastic Combined Chemotherapy Protocols--therapeutic use<br/>Bevacizumab<br/>Breast Neoplasms--drug therapy<br/>Decision Support Techniques<br/>Drug Administration Schedule<br/>Female<br/>Humans<br/>Middle Aged<br/>Prognosis<br/>Receptor, ErbB-2--metabolism<br/>Risk Assessment<br/>Risk Factors<br/>Survival Rate<br/>Taxoids--administration & dosage